Screening for prostate cancer

Clin Prostate Cancer. 2004 Jun;3(1):21-5. doi: 10.3816/cgc.2004.n.008.

Abstract

Prostate cancer is a highly prevalent disease in the Western world. In the United States alone, prostate cancer affects approximately 230,000 men and causes the death of 30,000 American men annually. Several theoretical health care measures may be implemented to decrease the morbidity and mortality of any disease. These measures include prevention, screening, improved curative treatment, and the transformation of an acute lethal disease to a chronic, tolerable one. This summary focuses on the screening aspects of prostate cancer.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / analysis
  • Cost-Benefit Analysis
  • Humans
  • Male
  • Mass Screening* / economics
  • Prevalence
  • Prognosis
  • Prostate-Specific Antigen / analysis*
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / epidemiology
  • Sensitivity and Specificity
  • Survival Analysis

Substances

  • Biomarkers, Tumor
  • Prostate-Specific Antigen